Sugi Predict

Sugi Predict / Compounds / SCHEMBL56916

SCHEMBL56916

SCHEMBL56916

CC(C)(C)OC(=O)NC1(CO)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.41
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ APLNR P35414 1/20 0.38
▸ CTSL P07711 1/20 0.38
▸ P2RX7 Q99572 1/20 0.36
▸ PPIA P62937 1/20 0.36
▸ CA1 P00915 2/20 0.36
▸ CA2 P00918 2/20 0.36
▸ CA7 P43166 2/20 0.36
▸ GAA P10253 1/20 0.35
▸ CTSK P43235 1/20 0.35
▸ CA12 O43570 2/20 0.34
▸ CA14 Q9ULX7 2/20 0.34
▸ EPHX1 P07099 1/20 0.34
▸ NFKB1 P19838 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ RELA Q04206 1/20 0.33
▸ GHSR Q92847 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10799485 0.93 TDP1 (0.40) TDP1MEN1KMT2AMAPK1APLNR
SCHEMBL1368840 0.93 P2RX7 (0.40) TDP1MEN1KMT2AMAPK1APLNR
SCHEMBL5521873 0.93 P2RX7 (0.42) TDP1MEN1KMT2AMAPK1APLNR
SCHEMBL12975362 0.91 P2RX7 (0.44) TDP1MEN1KMT2AMAPK1APLNR
SCHEMBL941564 0.91 P2RX7 (0.44) TDP1MEN1KMT2AMAPK1APLNR
SCHEMBL17606749 0.88 TDP1 (0.36) TDP1MEN1KMT2AMAPK1APLNR
SCHEMBL1667225 0.88 CTSL (0.39) TDP1MEN1KMT2AMAPK1APLNR
SCHEMBL22079844 0.87 HCRTR2 (0.35) TDP1MEN1KMT2AMAPK1APLNR
SCHEMBL23011175 0.87 DRD2 (0.36) TDP1MEN1KMT2AMAPK1APLNR
SCHEMBL18502867 0.85 KMT2A (0.35) TDP1MEN1KMT2AMAPK1APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144795-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2026-05-28 — — US disclosed
WO-2026103873-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF 杭州百新生物医药科技有限公司 2026-05-21 — — WO disclosed
US-12583866-B2 Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists BEONE MEDICINES I GMBH (CH) 2026-03-24 — — US disclosed
US-20260069602-A1 COMPOUNDS, COMPOSITIONS, AND METHODS ACONCAGUA BIO INC (US) 2026-03-12 — — US disclosed
US-20260042788-A1 STAT6 COMPOUNDS GILEAD SCIENCES INC (US) 2026-02-12 — — US disclosed
US-20250320197-A1 THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF ECCOGENE INC (US) 2025-10-16 — — US disclosed
US-20250276977-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC (US) 2025-09-04 — — US disclosed
EP-4606377-A2 NOVEL AMINO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2025-08-27 — — EP disclosed
EP-3980400-B1 PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS UNIV EMORY (US) 2025-08-06 — — EP disclosed
WO-2025149629-A1 NOVEL CARBOXAMIDE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2025-07-17 — — WO disclosed
US-20030220341-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy ANORMED, INC. (CA) 2003-11-27 — — US disclosed
WO-2003055876-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY ANORMED INC. (CA) 2003-07-10 — — WO disclosed
EP-1170281-A1 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof LES LABORATOIRES SERVIER (FR) 2002-01-09 — — EP disclosed
WO-2001040183-A1 1-AMINOALKYL-1H-INDOLES FOR TREATING GLAUCOMA ALCON UNIVERSAL LTD. (CH) 2001-06-07 — — WO disclosed
US-4698231-A Sweetening with L-aminodicarboxylic acid amides GENERAL FOOD CORPORATION (US) 1987-10-06 — — US disclosed
US-4654439-A FOOD SWEETENERS GENERAL FOODS CORPORATION (US) 1987-03-31 — — US disclosed
US-4650688-A DIPEPTIDES GENERAL FOODS CORPORATION (US) 1987-03-17 — — US disclosed
EP-0203539-A1 L-Aminodicarboxylic acid amides of alkoxyalkylamines and an edible composition containing same GENERAL FOODS CORPORATION (US) 1986-12-03 — — EP disclosed
US-4622418-A LOW CALORIE SWEETENERS GENERAL FOODS CORPORATION (US) 1986-11-11 — — US disclosed
US-4603011-A ARTIFICIAL SWEETRENERS GENERAL FOODS CORPORATION (US) 1986-07-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250276977-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 TDP1 252/4885MEN1 1061/4885KMT2A 42/4885
US-20260144795-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS HCRTR2, HCRTR1, CRHR1 TDP1 4786/4885MEN1 2106/4885KMT2A 2095/4885
US-20260042788-A1 STAT6 COMPOUNDS STAT6, IL6ST, NFATC1 TDP1 3845/4885MEN1 4198/4885KMT2A 1732/4885
US-12583866-B2 Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists BIRC2, BIRC3, BIRC5 TDP1 2011/4885MEN1 3715/4885KMT2A 4506/4885
US-20030220341-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy CCR5, CXCR4, CXCR3 TDP1 4428/4885MEN1 3210/4885KMT2A 3464/4885
US-20250320197-A1 THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF TSHR, THRA, THRB TDP1 936/4885MEN1 510/4885KMT2A 4108/4885
US-20260069602-A1 COMPOUNDS, COMPOSITIONS, AND METHODS SCTR, SSTR1, NPY1R TDP1 1946/4885MEN1 465/4885KMT2A 4817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.